Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Shanghai Microdom Biotech Co. Ltd. is addressing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners within 1 distinct art unit. This suggests that while different individuals are reviewing the company's applications, they all belong to the same specialized administrative group. Such a structure allows for some consistency in the examination environment while still involving multiple perspectives from 2 distinct examiners.
FRONDA, CHRISTIAN L is the busiest examiner for the portfolio, managing 1 pending office action. The presence of 2 distinct examiners for 2 pending actions shows that each examiner is currently responsible for one matter. This even distribution of the workload means that no single examiner is overwhelmed by the company's filings. For the practitioner, this indicates that each of the 2 pending office actions is receiving individual attention from different staff members within the same art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FRONDA, CHRISTIAN L | 1 | 82.5% | +14.3% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.8% | +41.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18032784 | PROTEOGLYCAN CONJUGATE AND APPLICATION THEREOF | OGUNBIYI, OLUWATOSIN A | 2d overdue |
| 18605800 | METHOD FOR PURIFYING TETANUS TOXIN OR VARIANTS THEREOF | FRONDA, CHRISTIAN L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18032784 | PROTEOGLYCAN CONJUGATE AND APPLICATION THEREOF | OGUNBIYI, OLUWATOSIN A | 2d overdue |
| 18605800 | METHOD FOR PURIFYING TETANUS TOXIN OR VARIANTS THEREOF | FRONDA, CHRISTIAN L | — |
| Art Unit | Apps |
|---|---|
| 1645 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18605800 | METHOD FOR PURIFYING TETANUS TOXIN OR VARIANTS THEREOF | FRONDA, CHRISTIAN L | 1645 | §102§103§112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18032784 | PROTEOGLYCAN CONJUGATE AND APPLICATION THEREOF | OGUNBIYI, OLUWATOSIN A | 1645 | §101§102§112 | Non-Final OA | 2d overdue | Pending | Apr 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Microdom Biotech Co. Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Christian L Fronda has the most, with 1 of Shanghai Microdom Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
